Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Top Cited Papers
Open Access
- 15 June 2007
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 109 (12), 5136-5142
- https://doi.org/10.1182/blood-2006-11-056754
Abstract
Nelarabine (506U78) is a soluble pro-drug of 9-β-d-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, and 5) at 1.5 g/m2/day. Cycles were repeated every 22 days. The median age was 34 years (range, 16-66 years); 32 (82%) patients were male. The rate of complete remission was 31% (95% confidence interval [CI], 17%, 48%) and the overall response rate was 41% (95% CI, 26%, 58%). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively. There was only one grade 4 adverse event of the nervous system, which was a reversible depressed level of consciousness. The median disease-free survival (DFS) was 20 weeks (95% CI, 11, 56), and the median overall survival was 20 weeks (95% CI, 13, 36). The 1-year overall survival was 28% (95% CI, 15%, 43%). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL.Keywords
This publication has 22 references indexed in Scilit:
- Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology GroupJournal of Clinical Oncology, 2005
- Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2005
- A single high dose of idarubicin combined with high‐dose ARA‐C for treatment of first relapse in childhood ‘high‐risk’ acute lymphoblastic leukaemia: a study of the AIEOP groupBritish Journal of Haematology, 2002
- Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2000
- Primary refractory and relapsed adult acute lymphoblastic leukemiaCancer, 1999
- Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.Journal of Clinical Oncology, 1998
- PHARMACOLOGIC PURGING OF MALIGNANT T CELLS FROM HUMAN BONE MARROW USING 9-β-D-ARABINOFURANOSYLGUANINETransplantation, 1991
- Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts.JCI Insight, 1984
- Purine nucleoside synthesis: an efficient method employing nucleoside phosphorylasesBiochemistry, 1981
- Synthesis of 9-β-D-Arabinofuranosylguanine*Biochemistry, 1964